TrialSpark, a tech-enabled drug development partner involved in improving the speed, quality and innovation of clinical trials, announced yesterday that it has named and Dr Ken Somberg as its new chief medical officer and Quentin Chu as its new president and chief financial officer.
After spending 12 years at Novartis where he served as the therapeutic area head for Clinical Research, and later in Regulatory Affairs for the Transplantation and Immunology Business Unit, Somberg joined Covance Inc as CMO in 2009. Most recently, Somberg served as CMO of Nevakar Inc, focusing on developing innovative products in injectable and ophthalmic therapeutics.
Prior to joining TrialSpark, Chu was CFO at CityMD, with experience in healthcare and private equity having served at Crestview Partners and The Carlyle Group.
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial